Selventa

Genstruct Appoints Dr. Michael Pavia to Its Board of Directors

Genstruct Appoints Dr. Michael Pavia to Its Board of Directors

February 14, 2005

CAMBRIDGE, Mass., Feb. 14 /PRNewswire/ -- Genstruct, Inc., a knowledge-driven discovery company using systems biology to discover biomarkers to increase the effectiveness of drug discovery and development, today announced the appointment of Michael R. Pavia, Ph.D., former chief technology officer (CTO) of Millennium Pharmaceuticals, to its Board of Directors.

BG Medicine, Inc.
Selventa

Cover Article in Chemical & Engineering News Features Flagship Portfolio Companies BG Medicine and Genstruct

Cover Article in Chemical & Engineering News Features Flagship Portfolio Companies BG Medicine and Genstruct

February 16, 2005

Two of Flagship's portfolio companies, BG Medicine and Genstruct, are featured in the cover article of this month's Chemical & Engineering News. Both are the result of Flagship's venture creation efforts over the past several years, and are recognized as leaders in the emerging field of Systems Biology. Both companies have also had significant, sustained involvement by Flagship as they have evolved and matured.

AVEO Pharmaceuticals, Inc.

GENPATH PHARMACEUTICALS BECOMES AVEO PHARMACEUTICALS

GENPATH PHARMACEUTICALS BECOMES AVEO PHARMACEUTICALS

March 1, 2005

Cambridge, MA, March 1, 2005 – GenPath Pharmaceuticals, Inc., a drug discovery and development company focused on the treatment of cancer and other diseases, announced today that it has changed its corporate name to AVEO Pharmaceuticals, Inc.

Morphotek, Inc.

Morphotek Announces Acceptance of Investigational New Drug Application for MORAb-003, a humanized monoclonal antibody for the treatment of advanced ovarian cancer

Morphotek Announces Acceptance of Investigational New Drug Application for MORAb-003, a humanized monoclonal antibody for the treatment of advanced ovarian cancer

March 28, 2005

Exton, PA, March 28, 2005– Morphotek, Inc. today announced that the United States Food and Drug Administration has accepted its Investigational New Drug (IND) Application for treatment of advanced ovarian cancer with MORAb-003, a humanized monoclonal antibody. The Phase I clinical study is designed as an open label single dose escalation safety study in patients with chemo-refractive ovarian cancer.

Black Duck Software, Inc.

Black Duck Launches protexIP/OnDemand Hosted Service To Analyze Software for Open Source License Compliance

Black Duck Launches protexIP/OnDemand Hosted Service To Analyze Software for Open Source License Compliance

March 28, 2005

Lets Software Developers, Outsourcers, and Due Diligence Teams Meet Compliance Deadlines with Easy-to-Use, Automated Service

Ensemble Therapeutics Corporation

Ensemble Discovery Names Richard F. Begley as CEO; Begley Leverages Knowledge of Chemistry, Biology and Engineering

Ensemble Discovery Names Richard F. Begley as CEO; Begley Leverages Knowledge of Chemistry, Biology and Engineering

April 4, 2005

CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 4, 2005--Ensemble Discovery Corporation, an early stage company developing a revolutionary approach to create new products in life Sciences, materials, and chemicals through its proprietary DNA Programmed Chemistry(TM) platform, has named Richard F. Begley, Ph.D., as president and chief executive officer.

Morphotek, Inc.

Morphotek Announces Multi-Year, Research Collaboration Agreement with Amgen to Optimize Expression of Antibodies

Morphotek Announces Multi-Year, Research Collaboration Agreement with Amgen to Optimize Expression of Antibodies

April 18, 2005

Exton, PA -- April 18, 2005 -- Morphotek Inc. today announced that it has entered into a multi-year Research Collaboration Agreement with Amgen Inc. to apply Morphotek's proprietary MORPHODOMA® technology to Amgen's proprietary cell lines to generate high-titer antibody producing cell lines for scaleable manufacturing.
 

Black Duck Software, Inc.

Black Duck Software Secures $12M in Series B Financing Led by Fidelity Ventures

Black Duck Software Secures $12M in Series B Financing Led by Fidelity Ventures

June 6, 2005

With Participation from Intel, SAP Ventures, and Original Investors Flagship Ventures, General Catalyst Partners, and Red Hat

IntelliVid

IntelliVid Announces Funding

IntelliVid Announces Funding

June 7, 2005

Company Offers Groundbreaking Intelligent Video Analysis Solutions for Retail Loss Prevention

Brainshark, Inc.

Brainshark, Inc. Secures $6.9 Million Financing in Oversubscribed Round

Brainshark, Inc. Secures $6.9 Million Financing in Oversubscribed Round

June 13, 2005

Bullish Outlook For Company's Leadership in Rapidly Growing Segment of Web-based Communications Market Attracts Investment from New and Existing Investors to Fund Expansion